HIV disease activity as a modulator of lipoprotein(a) and allele-specific apolipoprotein(a) levels

Arteriosclerosis, Thrombosis, and Vascular Biology

Volumn 33, Issue 2, 2013, Pages 387-392

  Enkhmaa, Byambaa ^a   Anuurad, Erdembileg ^a   Zhang, Wei ^a   Abbuthalha, Adnan ^a   Li, Xiao Dong ^a   Dotterweich, William ^c   Pollard, Richard B ^a   Asmuth, David M ^a,b   Berglund, Lars ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

^c UNIVERSITY OF NOTRE DAME   (United States)

Author keywords

apo(a) size; cardiovascular risk; CD4+ T cells; HIV; Lp(a)

Indexed keywords

APOLIPOPROTEIN A; LIPOPROTEIN A; VIRUS RNA;

ADULT; ALLELE; ARTICLE; CD4 LYMPHOCYTE COUNT; DISEASE ACTIVITY; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LIPOPROTEIN BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; VIRUS LOAD;

ADULT; AFRICAN AMERICANS; APOPROTEIN(A); BIOLOGICAL MARKERS; CALIFORNIA; CARDIOVASCULAR DISEASES; CD4 LYMPHOCYTE COUNT; CROSS-SECTIONAL STUDIES; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; HIV; HIV INFECTIONS; HUMANS; LIPOPROTEIN(A); MALE; MIDDLE AGED; PARTICLE SIZE; PROGNOSIS; RISK FACTORS; RNA, VIRAL; VIRAL LOAD;

EID: 84872973234     PISSN: 10795642     EISSN: 15244636     Source Type: Journal    
DOI: 10.1161/ATVBAHA.112.300125     Document Type: Article

References (38)

1. Roger VL, Go AS, Lloyd-Jones DM, Benjamin EJ, Berry JD, Borden WB, et al. Heart disease and stroke statistics-2012 update: a report from the American Heart Association. Circulation. 2012;125:e2-e220.
2. Mathers CD, Loncar D. Projections of global mortality and burden of disease from 2002 to 2030. PLoS Med. 2006;3:e442.
3. Islam FM, Wu J, Jansson J, Wilson DP. Relative risk of cardiovascular disease among people living with HIV: a systematic review and meta-analysis. HIV Med. 2012;13:453-468.
4. Tebas P, Henry WK, Matining R, Weng-Cherng D, Schmitz J, Valdez H, Jahed N, Myers L, Powderly WG, Katzenstein D. Metabolic and immune activation effects of treatment interruption in chronic HIV-1 infection: implications for cardiovascular risk. PLoS ONE. 2008;3:e2021.
5. El-Sadr WM, Lundgren JD, Neaton JD, Gordin F, Abrams D, Arduino RC, et al. CD4+ count-guided interruption of antiretroviral treatment. N Engl J Med. 2006;355:2283-2296.
6. Erqou S, Kaptoge S, Perry PL, Di Angelantonio E, Thompson A, White IR, Marcovina SM, Collins R, Thompson SG, Danesh J; Emerging Risk Factors Collaboration. Lipoprotein(a) concentration and the risk of coronary heart disease, stroke, and nonvascular mortality. JAMA. 2009;302:412-423.
7. Kamstrup PR, Tybjaerg-Hansen A, Steffensen R, Nordestgaard BG. Genetically elevated lipoprotein(a) and increased risk of myocardial infarction. JAMA. 2009;301:2331-2339.
8. Nordestgaard BG, Chapman MJ, Ray K, Borén J, Andreotti F, Watts GF, et al. Lipoprotein(a) as a cardiovascular risk factor: current status. Eur Heart J. 2010;31:2844-2853.
9. Boerwinkle E, Leffert CC, Lin J, Lackner C, Chiesa G, Hobbs HH. Apolipoprotein(a) gene accounts for greater than 90% of the variation in plasma lipoprotein(a) concentrations. J Clin Invest. 1992; 90:52-60.
10. Koschinsky ML, Beisiegel U, Henne-Bruns D, Eaton DL, Lawn RM. Apolipoprotein(a) size heterogeneity is related to variable number of repeat sequences in its mRNA. Biochemistry. 1990;29:640-644.
11. Lackner C, Boerwinkle E, Leffert CC, Rahmig T, Hobbs HH. Molecular basis of apolipoprotein (a) isoform size heterogeneity as revealed by pulsed-feld gel electrophoresis. J Clin Invest. 1991;87:2153-2161.
12. Marcovina SM, Albers JJ, Wijsman E, Zhang Z, Chapman NH, Kennedy H. Differences in Lp[a] concentrations and apo[a] polymorphs between black and white Americans. J Lipid Res. 1996;37:2569-2585.
13. Parra HJ, Luyéyé I, Bouramoué C, Demarquilly C, Fruchart JC. Black-white differences in serum Lp(a) lipoprotein levels. Clin Chim Acta. 1987;168:27-31.
14. Sandholzer C, Hallman DM, Saha N, Sigurdsson G, Lackner C, Császár A, Boerwinkle E, Utermann G. Effects of the apolipoprotein(a) size polymorphism on the lipoprotein(a) concentration in 7 ethnic groups. Hum Genet. 1991;86:607-614.
15. Paultre F, Pearson TA, Weil HF, Tuck CH, Myerson M, Rubin J, Francis CK, Marx HF, Philbin EF, Reed RG, Berglund L. High levels of Lp(a) with a small apo(a) isoform are associated with coronary artery disease in African American and white men. Arterioscler Thromb Vasc Biol. 2000;20:2619-2624.
16. Rubin J, Paultre F, Tuck CH, Holleran S, Reed RG, Pearson TA, Thomas CM, Ramakrishnan R, Berglund L. Apolipoprotein [a] genotype infuences isoform dominance pattern differently in African Americans and Caucasians. J Lipid Res. 2002;43:234-244.
17. Anuurad E, Rubin J, Chiem A, Tracy RP, Pearson TA, Berglund L. High levels of infammatory biomarkers are associated with increased allele-specifc apolipoprotein(a) levels in African-Americans. J Clin Endocrinol Metab. 2008;93:1482-1488.
18. McGowan MW, Artiss JD, Strandbergh DR, Zak B. A peroxidase-cou-pled method for the colorimetric determination of serum triglycerides. Clin Chem. 1983;29:538-542.
19. Allain CC, Poon LS, Chan CS, Richmond W, Fu PC. Enzymatic determination of total serum cholesterol. Clin Chem. 1974;20:470-475.
20. Warnick GR, Benderson J, Albers JJ. Dextran sulfate-Mg2+ precipitation procedure for quantitation of high-density-lipoprotein cholesterol. Clin Chem. 1982;28:1379-1388.
21. Dembinski T, Nixon P, Shen G, Mymin D, Choy PC. Evaluation of a new apolipoprotein(a) isoform-independent assay for serum Lipoprotein(a). Mol Cell Biochem. 2000;207:149-155.
22. Enkhmaa B, Anuurad E, Zhang W, Pearson TA, Berglund L. Association of Lp-PLA(2) activity with allele-specifc Lp(a) levels in a bi-ethnic population. Atherosclerosis. 2010;211:526-530.
23. Triant VA, Lee H, Hadigan C, Grinspoon SK. Increased acute myo-cardial infarction rates and cardiovascular risk factors among patients with human immunodefciency virus disease. J Clin Endocrinol Metab. 2007;92:2506-2512.
24. Lang S, Mary-Krause M, Cotte L, Gilquin J, Partisani M, Simon A, Boccara F, Bingham A, Costagliola D; French Hospital Database on HIV-ANRS CO4. Increased risk of myocardial infarction in HIV-infected patients in France, relative to the general population. AIDS. 2010;24:1228-1230.
25. Anuurad E, Semrad A, Berglund L. Human immunodefciency virus and highly active antiretroviral therapy-associated metabolic disorders and risk factors for cardiovascular disease. Metab Syndr Relat Disord. 2009;7:401-410.
26. Friis-Møller N, Sabin CA, Weber R, d'Arminio Monforte A, El-Sadr WM, Reiss P, et al. Combination antiretroviral therapy and the risk of myocardial infarction. N Engl J Med. 2003;349:1993-2003.
27. Friis-Møller N, Reiss P, Sabin CA, Weber R, Monforte A, El-Sadr W, Thiébaut R, De Wit S, Kirk O, Fontas E, Law MG, Phillips A, Lundgren JD; DAD Study Group. Class of antiretroviral drugs and the risk of myo-cardial infarction. N Engl J Med. 2007;356:1723-1735.
28. Sabin CA, Worm SW, Weber R, Reiss P, El-Sadr W, Dabis F, et al. Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients enrolled in the D:A:D study: a multi-cohort collaboration. Lancet. 2008;371:1417-1426.
29. Mary-Krause M, Cotte L, Simon A, Partisani M, Costagliola D; Clinical Epidemiology Group from the French Hospital Database. Increased risk of myocardial infarction with duration of protease inhibitor therapy in HIV-infected men. AIDS. 2003;17:2479-2486.
30. Périard D, Telenti A, Sudre P, Cheseaux JJ, Halfon P, Reymond MJ, Marcovina SM, Glauser MP, Nicod P, Darioli R, Mooser V. Atherogenic dyslipidemia in HIV-infected individuals treated with protease inhibitors. The Swiss HIV Cohort Study. Circulation. 1999;100:700-705.
31. Constans J, Pellegrin JL, Peuchant E, Dumon MF, Simonoff M, Clerc M, Leng B, Conri C. High plasma lipoprotein (a) in HIV-positive patients. Lancet. 1993;341:1099-1100.
32. Kritz H, Efthimiou Y, Stamatopoulos J, Najemnik C, Sinzinger H. Association of lipoprotein(a), prostaglandin I(2)-synthesis stimulating plasma factor, biological half-life of prostaglandin I(2)and high-density lipoproteins in HIV-1 infection of different stages. Prostaglandins Leukot Essent Fatty Acids. 2000;63:309-314.
33. Rader DJ, Cain W, Zech LA, Usher D, Brewer HB Jr. Variation in lipoprotein(a) concentrations among individuals with the same apolipo-protein (a) isoform is determined by the rate of lipoprotein(a) production. J Clin Invest. 1993;91:443-447.
34. Moliterno DJ, Jokinen E V, Miserez AR, Lange RA, Willard JE, Boerwinkle E, Hillis LD, Hobbs HH. No association between plasma lipoprotein(a) concentrations and the presence or absence of coronary atherosclerosis in African-Americans. Arterioscler Thromb Vasc Biol. 1995;15:850-855.
35. Sorrentino MJ, Vielhauer C, Eisenbart JD, Fless GM, Scanu AM, Feldman T. Plasma lipoprotein (a) protein concentration and coronary artery disease in black patients compared with white patients. Am J Med. 1992;93:658-662.
36. Palella FJ Jr, Gange SJ, Benning L, Jacobson L, Kaplan RC, Landay AL, Tracy RP, Elion R. Infammatory biomarkers and abacavir use in the Women's Interagency HIV Study and the Multicenter AIDS Cohort Study. AIDS. 2010;24:1657-1665.
37. Musselwhite LW, Sheikh V, Norton TD, Rupert A, Porter BO, Penzak SR, Skinner J, Mican JM, Hadigan C, Sereti I. Markers of endothe-lial dysfunction, coagulation and tissue fbrosis independently predict venous thromboembolism in HIV. AIDS. 2011;25:787-795.
38. Ford ES, Greenwald JH, Richterman AG, Rupert A, Dutcher L, Badralmaa Y, Natarajan V, Rehm C, Hadigan C, Sereti I. Traditional risk factors and D-dimer predict incident cardiovascular disease events in chronic HIV infection. AIDS. 2010;24:1509-1517.